中国专家在肝癌治疗领域获得突破 - 2020年08月05日

Local experts have completed the nation’s first genetic map on patients with intrahepatic cholangiocarcinoma, the second most common liver cancer, to provide evidence and information for precise treatment such as targeted medicine and immunotherapy development.
The study was published by the world leading Journal of Translational Medicine, said officials from the Shanghai Cancer Center.
The cancer accounts for 15 to 20 percent of liver cancer cases. As there are no special symptoms at an early stage, about 65 percent of patients have been in the terminal stage when diagnosed.